Recall(New to the series?)
Dual agonists combine GLP-1R activation with either GIPR (GIP) or GCGR (glucagon). GIP synergizes with GLP-1 in fat tissue and the brain to amplify weight loss. Glucagon raises energy expenditure and drives hepatic fat mobilization. For the full receptor breakdown, see The Receptor Game.
The dual agonist family was built around one question: what happens when you activate two receptors instead of one? The answer, once tirzepatide hit Phase 3, was clear — you break the 15% weight loss ceiling that single GLP-1 agonists couldn't get past.
The family splits into two mechanistic branches that take different theories of how to do that.
The two branches
GLP-1 + GIP is the commercially proven branch. Tirzepatide activates both GLP-1R and GIPR with roughly equal potency. The GIP mechanism was controversial going in — early research suggested GIP might oppose weight loss. Tirzepatide's ~21% weight loss in SURMOUNT-1 ended that debate. GIPR activation in fat tissue and the brain amplifies GLP-1's appetite signal through pathways that are still being characterized mechanistically.
GLP-1 + glucagon is the mechanistically distinct branch. Glucagon is canonically a glucose-raising hormone — the last thing you'd think to add to a diabetes or obesity drug. But GCGR activation also raises resting energy expenditure and drives hepatic fat oxidation, effects that GLP-1 alone doesn't have. The glucagon component theoretically counters the metabolic rate adaptation that limits weight loss over time, and it directly targets the liver — which is why this branch is particularly relevant for MASH (metabolic dysfunction-associated steatohepatitis).
The key difference between the branches: GLP-1/GIP amplifies appetite suppression, GLP-1/glucagon adds metabolic rate. They're not redundant — they're solving different parts of the weight loss problem.
What defines dual agonism
Breaking the ceiling — dual agonists reliably reach 19–21% weight loss in well-powered Phase 3 trials, vs ~15% for single GLP-1 agonists. The SURMOUNT-5 head-to-head (tirzepatide vs semaglutide 2.4mg, 2025) confirmed ~47% greater relative weight loss for the dual agonist.
The glucagon balance problem — GCGR activation raises blood glucose via hepatic glucose production, which partially opposes GLP-1's insulin-stimulating effect. GLP-1/glucagon dual drugs require careful dose titration to balance these competing effects, particularly in non-diabetic patients. GLP-1/GIP drugs don't have this complication since GIPR doesn't directly affect glucose in the same way.
MASH as an indication — the GLP-1/glucagon branch has the strongest mechanistic case for liver disease. Glucagon drives hepatic fat oxidation directly. Survodutide's Phase 2 MASH data (~67% resolution without fibrosis worsening) reflects this. GLP-1/GIP drugs produce MASH improvement through weight loss alone; GLP-1/glucagon drugs add a direct liver mechanism on top of that.
Summary(The dual agonist picture)
Dual agonism reliably outperforms single GLP-1 agonism. Tirzepatide proved the GLP-1/GIP approach at commercial scale. The GLP-1/glucagon branch adds energy expenditure and liver targeting that GIP doesn't provide — particularly relevant for MASH. The head-to-head between the two branches is the open question this family will answer over the next 2–3 years.
Tirzepatide
At a glance
| Field | Details |
|---|---|
| Brand names | Mounjaro (T2D), Zepbound (obesity) |
| Targets | GLP-1R + GIPR |
| Developer | Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Approved — US (Mounjaro 2022, Zepbound 2023) |
| Key efficacy | 20.9% weight loss at 72 weeks (15mg, SURMOUNT-1) |
| Indications | Type 2 diabetes, obesity, sleep apnea |
User Sentiment
Tirzepatide has one of the most active patient communities of any prescription drug online. The dominant theme isn't weight loss — it's the degree to which food stops being a preoccupation. People describe it as "my brain just stopped thinking about food." That effect appears stronger than semaglutide reports at comparable doses.
Example(What the community says)
r/Mounjaro has over 200,000 members. The posts that resonate most aren't milestone weigh-ins — they're moments of realization. "I forgot to eat lunch." "I left half a pizza and genuinely didn't care." "I ordered the small and it was enough." People aren't describing willpower. They're describing a relationship with food that just changed.
How it works
A synthetic peptide engineered to activate both GLP-1R and GIPR with roughly equal potency from a single molecule. Half-life approximately 5 days, enabling once-weekly dosing. The dual receptor engagement is built into the peptide's amino acid sequence — not a conjugate of two separate drugs.
GLP-1R drives appetite suppression, insulin secretion, and gastric slowing. GIPR activation in fat tissue and the brain synergizes with GLP-1's satiety signal through mechanisms still being characterized — early research had suggested GIP agonism might be counterproductive for weight loss. Tirzepatide's Phase 3 results proved that assumption wrong at the dose levels achieved by a co-agonist molecule.
Intuition(Why GIP was controversial going in)
Early research on GIP suggested it might oppose weight loss — GIP receptor knockout mice in some studies were leaner than normal mice. The prevailing theory said GIP was a bad addition to a weight loss drug. Tirzepatide's Phase 3 data at 20.9% weight loss proved that theory wrong at the dose and potency levels achievable with a co-agonist molecule. The mechanism isn't fully resolved — but the clinical result was clear enough that the controversy is now mostly historical.
Trial data
SURMOUNT-1 (obesity, non-diabetic, 72 weeks): 20.9% mean weight loss on 15mg. ~37% of participants lost more than 25% of body weight. The 5mg and 10mg doses showed 15% and 19.5% respectively — all doses outperforming semaglutide 2.4mg's 15%.
SURPASS trials (T2D): 1.5–2.4% HbA1c reduction depending on dose, outperforming both insulin glargine and semaglutide.
SURMOUNT-5 (head-to-head vs semaglutide 2.4mg, 2025): tirzepatide produced ~47% greater relative weight loss — the definitive comparison establishing dual agonism's superiority over the single-receptor standard of care.
SURMOUNT-OSA (sleep apnea): significant reduction in apnea-hypopnea index, leading to approval for obstructive sleep apnea in 2024.
What to Expect
Weeks 1–4 — Nausea during dose escalation. More common at 5mg than at 2.5mg — the slow titration exists for a reason. Eating smaller portions, avoiding fatty or spicy food early on helps.
Month 2–3 — Food noise reduction becomes noticeable. Weight loss of 5–8% typical by this point for most people.
Month 4–6 — On 10–15mg maintenance, this is where the larger losses land. 15%+ weight loss by month 6 is common.
Month 6–18 — Weight loss continues. SURMOUNT-1 ran 72 weeks and the curve hadn't fully plateaued. Many patients report ongoing loss well past the 6-month mark.
Dosing and administration
2.5mg weekly → 5mg → 7.5mg → 10mg → 12.5mg → 15mg maintenance over ~20 weeks. Slow titration to manage GI tolerability. Single-dose autoinjector pen.
Development status
| Milestone | Status |
|---|---|
| Mounjaro (T2D) | Approved US 2022 |
| Zepbound (obesity) | Approved US 2023 |
| Sleep apnea indication | Approved US 2024 |
| SURMOUNT-MMO (CVD outcomes) | Ongoing — results expected 2027 |
| Heart failure indication | In development |
Safety profile
GI side effects — nausea, vomiting, diarrhea — most common during titration, pattern similar to semaglutide. Same thyroid C-cell black box warning as class. Heart rate increase of ~2–4 bpm. No novel safety signals identified in post-marketing surveillance beyond class effects.
Who It's For
- BMI ≥ 30, or ≥ 27 with type 2 diabetes, high blood pressure, sleep apnea, or cardiovascular disease
- Type 2 diabetes patients — Mounjaro is FDA-approved specifically for T2D alongside Zepbound for obesity
- People who tried semaglutide and want more — SURMOUNT-5 confirmed tirzepatide produces ~47% more weight loss
- Adults with obstructive sleep apnea — a specific approved indication
Finding a clinic that prescribes tirzepatide is the next step. Eligibility is straightforward and most qualifying conversations take one appointment.
Summary(The tirzepatide picture)
The drug that proved dual receptor targeting works at commercial scale. SURMOUNT-5 put a number on the advantage — 47% greater relative weight loss vs semaglutide. The current approved efficacy standard, pending Phase 3 data from retatrutide and the next generation of dual and triple agonists.
VK2735
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GIPR |
| Developer | Viking Therapeutics |
| Modality | SC injection weekly / oral tablet daily (separate formulations) |
| Approval status | Phase 3 |
| Key efficacy | 14.7% at 13 weeks (sub-Q Phase 2); ~8.2% at 13 weeks (oral Phase 2) |
| Indications | Obesity, T2D |
User Sentiment
VK2735 is still in clinical trials, so patient community data is from trial participants and early research followers rather than a broad prescriber base. Interest is high specifically around the oral formulation — people who want GLP-1 drug benefits without injections are watching Phase 3 closely.
Example(What trial participants report)
Phase 2 VENTURE participants reported weight loss and appetite reduction consistent with the tirzepatide class, with a tolerability profile similar to injectable GLP-1/GIP drugs. The oral Phase 2 cohort noted the convenience difference vs Rybelsus specifically — no fasting requirement, no timing restrictions.
How it works
GLP-1/GIP dual agonist with the same mechanistic framework as tirzepatide — simultaneous GLP-1R and GIPR activation from a single peptide. The strategic differentiation is in delivery: Viking is developing both an injectable and a separate oral small-molecule formulation. If the oral dual agonist holds up in Phase 3, VK2735 would be the first drug combining dual receptor efficacy with oral convenience.
Intuition(Why an oral dual agonist is structurally different from oral semaglutide)
Oral semaglutide (Rybelsus) requires an absorption enhancer, strict fasting, and achieves lower systemic exposure than injectable semaglutide — all because peptides are degraded in the gut. VK2735's oral formulation is a small molecule (not a peptide), so it doesn't need any of those workarounds. It survives gut transit, absorbs through conventional mechanisms, and has no food or timing restrictions. If Phase 3 confirms dual-agonist efficacy (~19–21% range) in a once-daily pill with no restrictions, the market comparison is to Rybelsus — not to injectable drugs.
Trial data
VENTURE (sub-Q Phase 2, 13 weeks): 14.7% weight loss. Short duration makes direct comparison to tirzepatide's 72-week numbers difficult, but the trajectory suggests competitive efficacy at full trial length.
ACHIEVE-1 (oral Phase 2, 13 weeks): ~8.2% weight loss — strong for an oral agent at this timepoint, better than oral semaglutide (Rybelsus) at comparable duration, and meaningful as a dual-agonist oral candidate.
What to Expect
Sub-Q formulation (once-weekly): Based on Phase 2 trajectory, expect a tirzepatide-like arc — GI side effects during escalation, food noise reduction by month 2, meaningful weight loss by month 3–4.
Oral formulation (once-daily): Phase 2 showed ~8.2% at 13 weeks — early, but strong for an oral agent. No food restrictions. Tolerability data pending at longer duration in Phase 3.
Not yet available for prescription — Phase 3 data expected before 2027 filing.
Dosing and administration
Sub-Q: once-weekly injection. Oral: once-daily tablet. Phase 3 titration schedules [verify final protocols].
Development status
| Milestone | Status |
|---|---|
| Sub-Q Phase 2 | Complete — 14.7% at 13 weeks |
| Oral Phase 2 | Complete — 8.2% at 13 weeks |
| Sub-Q Phase 3 | Enrolling |
| Oral Phase 3 | Enrolling |
| FDA filing | ~2027 estimated |
Safety profile
Phase 2 GI profile consistent with GLP-1/GIP class. No novel safety signals identified in either formulation. Full tolerability picture pending Phase 3 at longer duration.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- People who want dual-agonist efficacy (~19–21% range) but prefer or require oral delivery
- Injection-averse patients who've been waiting for an oral option with better efficacy than current choices
Watch Phase 3 results — if the oral formulation confirms Phase 2 efficacy, this becomes the first real dual-agonist pill and the access implications are significant.
Summary(The VK2735 picture)
The dual agonist race's oral candidate. Sub-Q Phase 3 is the near-term bet; the oral Phase 3 is the long-term prize. First dual-agonist pill to reach Phase 3 approval would change the access and cost equation for the entire GLP-1/GIP segment.
Olatorepatide
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GIPR |
| Developer | Hansoh Pharma / Regeneron |
| Modality | SC injection, once-weekly |
| Approval status | Phase 3 |
| Key efficacy | 19.3% weight loss at 48 weeks (Phase 3, Chinese cohort) |
| Indications | Obesity |
User Sentiment
Olatorepatide's patient community is currently limited to Chinese trial participants. The Regeneron partnership has raised its profile among people tracking the GLP-1 pipeline, but Western prescription data doesn't exist yet.
Example(What Phase 3 participants report)
Chinese OASIS-1 trial participants at 19.3% weight loss at 48 weeks are reporting outcomes consistent with tirzepatide-level response. Community posts from Chinese health forums describe the appetite suppression as strong and consistent with the dual-agonist class experience.
How it works
GLP-1/GIP dual agonist — same mechanistic framework as tirzepatide, single peptide activating both GLP-1R and GIPR simultaneously. The Regeneron partnership provides US development infrastructure for a drug originating from Hansoh Pharma, one of the larger Chinese pharmaceutical companies investing in the GLP-1 space.
Note(The China-to-global pipeline model)
Olatorepatide follows a pattern becoming common in GLP-1 development: a Chinese pharma (Hansoh) generates Phase 3 data domestically, validates the molecule, then partners with a Western company (Regeneron) for US/EU filing and commercialization. The Chinese Phase 3 data establishes proof of efficacy; the global Phase 3 satisfies Western regulatory requirements with a more diverse population. It's faster and cheaper than starting global Phase 3 from scratch.
Trial data
OASIS-1 (Phase 3, Chinese cohort): 19.3% weight loss at 48 weeks — competitive with tirzepatide's 19.5% at 10mg and 72 weeks. Cross-trial comparison is imprecise due to different populations and durations, but the magnitude is consistent with the GLP-1/GIP dual agonist class range. Global Phase 3 trials ongoing.
What to Expect
Based on Phase 3 Chinese cohort data and GLP-1/GIP dual mechanism:
Month 1–2 — GI side effects during escalation similar to tirzepatide class. Appetite reduction reported early.
Month 3–6 — 10–15% weight loss range expected based on trajectory.
Month 6–12 — Phase 3 data at 48 weeks showed 19.3% — the curve consistent with ongoing loss through the trial period.
Not yet available in the US or EU — global Phase 3 enrollment and readout timeline is the next milestone to watch.
Dosing and administration
Once-weekly subcutaneous injection. Full titration schedule to be confirmed in global Phase 3 [verify].
Development status
| Milestone | Status |
|---|---|
| Phase 3 Chinese cohort | Data reported — 19.3% at 48 weeks |
| Global Phase 3 | Enrolling |
| FDA filing | Pending global Phase 3 data — [verify timeline] |
Safety profile
GI profile consistent with GLP-1/GIP class based on Phase 3 Chinese cohort data. Global safety database pending completion of global trials.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- Type 2 diabetes patients — both indications in development
- Not currently available outside China — global Phase 3 will determine US/EU availability timeline
If you're tracking the GLP-1 pipeline for future options, olatorepatide is one to follow as Regeneron moves through global filing.
Summary(The olatorepatide picture)
19.3% weight loss at 48 weeks in Phase 3 (Chinese cohort) puts it in the tirzepatide range. Global Phase 3 is the registration path. The Regeneron partnership gives it Western commercial infrastructure — watch the global Phase 3 enrollment and readout timeline vs competitors.
Survodutide
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GCGR |
| Developer | Boehringer Ingelheim / Zealand Pharma |
| Modality | SC injection, once-weekly |
| Approval status | Phase 3 |
| Key efficacy | ~19% weight loss at 46 weeks (Phase 2, obesity) |
| Indications | Obesity, MASH |
User Sentiment
Survodutide's community is primarily MASH patients and their caregivers — a group that's been watching GLP-1/glucagon data closely because MASH had almost no pharmacological treatment options until recently. The obesity trial participants report strong appetite suppression, with the glucagon component noted as producing a distinct "metabolic shift" feeling beyond standard GLP-1 effects.
Example(What the community says)
MASH patient forums light up around survodutide Phase 2 data in ways that weight loss posts don't — because for that population, a drug showing 67% MASH resolution represents the first real pharmacological option for a condition that previously had none. The emotional stakes in those communities are different from pure obesity treatment discussions.
How it works
GLP-1/glucagon dual agonist — mechanistically distinct from the GLP-1/GIP branch. GLP-1R drives appetite suppression and insulin secretion. GCGR activation adds resting energy expenditure and hepatic fat oxidation — effects that GLP-1 alone and GLP-1/GIP drugs don't provide. The glucagon component directly mobilizes fat from the liver, which is the primary reason survodutide is the leading drug in the MASH indication alongside its obesity development.
Intuition(Why glucagon is good for the liver)
Glucagon is best known for raising blood glucose by stimulating hepatic glucose production — the opposite of what you want in a diabetes or obesity drug. But glucagon also directly activates fat oxidation in the liver, driving hepatic fat breakdown independent of weight loss. MASH (metabolic dysfunction-associated steatohepatitis) is driven by hepatic fat accumulation and the inflammation that follows. GLP-1 drugs improve MASH through weight loss. GLP-1/glucagon drugs add a direct liver mechanism on top of that — which is why survodutide's 67% MASH resolution rate in Phase 2 is higher than any pure weight-loss drug would predict.
Trial data
Phase 2 obesity (46 weeks): ~19% weight loss — competitive with tirzepatide's Phase 2 numbers, though different populations and doses limit direct comparison.
Phase 2 MASH: ~67% of patients achieved MASH resolution without worsening of fibrosis — a striking number in a disease where lifestyle modification had been the primary treatment until recently. The glucagon agonism mechanism driving hepatic fat oxidation is believed to underlie this effect.
What to Expect
Weeks 1–4 — Slower titration than tirzepatide due to the glucagon component requiring careful glucose management. GI side effects similar to class, nausea most common.
Month 2–4 — Appetite reduction and energy expenditure increase both reported — the latter is distinct from GLP-1-only drugs and reflects the GCGR component at work.
Month 6+ — Phase 2 weight loss of ~19% at 46 weeks puts the expected trajectory in the tirzepatide range. MASH patients: liver fat reduction and histology improvement typically visible in blood markers and imaging within 6 months.
Dosing and administration
Once-weekly subcutaneous injection. Slower titration schedule than GLP-1-only drugs due to glucagon's glucose-raising effect requiring careful balance. Phase 3 titration schedule [verify against final protocol].
Development status
| Milestone | Status |
|---|---|
| Phase 2 obesity | Complete — ~19% weight loss |
| Phase 2 MASH | Complete — ~67% resolution |
| Phase 3 obesity | Enrolling |
| Phase 3 MASH | Enrolling |
| FDA filing | ~2027 estimated |
Safety profile
GI profile similar to GLP-1 class. Glucagon component raises theoretical hyperglycemia concern in non-diabetic patients — manageable within dose ranges tested in Phase 2 through careful titration. Heart rate elevation similar to class. Phase 3 will be the definitive tolerability read at longer duration.
Who It's For
- BMI ≥ 30 or ≥ 27 with a weight-related condition
- MASH patients specifically — if you have metabolic liver disease, survodutide's Phase 2 data is the most compelling pharmacological signal for this indication
- People who haven't responded fully to GLP-1-only approaches and want the added energy expenditure from glucagon agonism
Currently Phase 3 — not yet available for prescription. Talk to a hepatologist or endocrinologist about trial eligibility if you have MASH.
Summary(The survodutide picture)
~19% Phase 2 weight loss is competitive with the GLP-1/GIP branch. The MASH resolution data (~67% without fibrosis worsening) is the clinically distinctive number — potentially the highest ever seen for a pharmacological agent in liver disease. If Phase 3 confirms both, survodutide has two registration paths: obesity and MASH as distinct indications.
Pemvidutide
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GCGR |
| Developer | Altimmune |
| Modality | SC injection, once-weekly |
| Approval status | Phase 2 complete, Phase 3 pending |
| Key efficacy | ~15.6% weight loss at 48 weeks (Phase 2 MOMENTUM) |
| Indications | Obesity, MASH |
User Sentiment
Pemvidutide's community is small and primarily clinical trial participants and MASH-focused patient advocates. Obesity trial participants noted strong appetite suppression consistent with the dual-agonist class.
Example(What trial participants report)
IMPACT NASH participants tracking liver outcomes report the combination of weight loss and what appears to be direct liver fat reduction — a distinction they notice in imaging and enzyme markers that improves faster than weight loss alone would predict. The metabolic liver disease community has been watching this specifically.
How it works
GLP-1/glucagon dual with a development strategy that prioritizes MASH alongside obesity. Same mechanistic framework as survodutide: GLP-1R for appetite and insulin, GCGR for energy expenditure and hepatic fat oxidation. Glucagon agonism targets the liver directly — relevant to MASH because the disease is characterized by excessive hepatic fat accumulation and inflammation driven by metabolic dysfunction.
Note(MASH as a registration strategy)
Competing head-to-head with tirzepatide on obesity weight loss is a difficult position — tirzepatide has Phase 3 data, approval, and market share. Competing on MASH is a different game: the indication is distinct, the patient population is different, and the mechanism (direct hepatic fat oxidation via glucagon) gives GLP-1/glucagon drugs a biological argument that GLP-1/GIP drugs can't match. Pemvidutide is explicitly pursuing MASH as its primary registration indication — not a consolation prize, but a deliberate strategy.
Trial data
MOMENTUM (Phase 2, obesity, 48 weeks): ~15.6% weight loss — below survodutide's Phase 2 numbers but within a design not optimized purely for weight loss endpoint.
IMPACT NASH (Phase 2, MASH): Significant hepatic fat reduction and improvement in liver histology scores. Moving toward Phase 3 with MASH as the primary registration indication.
What to Expect
Month 1–3 — GI side effects during escalation, appetite reduction typical of dual-agonist class.
Month 3–6 — 10–12% weight loss range based on MOMENTUM Phase 2 trajectory.
Liver markers — For MASH patients, ALT and AST improvements often visible within 3 months of starting treatment; imaging changes take longer.
Not yet available for prescription — Phase 3 pending. MASH indication is the primary development target.
Dosing and administration
Once-weekly subcutaneous injection. Titration details to be confirmed in Phase 3 [verify].
Development status
| Milestone | Status |
|---|---|
| Phase 2 MOMENTUM (obesity) | Complete — 15.6% at 48 weeks |
| Phase 2 IMPACT NASH | Complete — significant liver improvement |
| Phase 3 initiation | Pending — MASH primary indication |
| FDA filing | ~2028 estimated |
Safety profile
GI profile consistent with GLP-1/glucagon class. Glucagon component managed through titration. No novel safety signals in Phase 2.
Who It's For
- Adults with MASH (metabolic dysfunction-associated steatohepatitis) — particularly those with elevated liver enzymes and confirmed steatosis
- BMI ≥ 30 or ≥ 27 with obesity-related metabolic conditions
- People whose hepatologist is recommending pharmacological intervention for liver disease alongside weight management
Ask your hepatologist specifically about GLP-1/glucagon dual agonists if you've been diagnosed with MASH — this is the mechanism class with the strongest liver-specific data.
Summary(The pemvidutide picture)
Phase 2 weight loss below the dual-agonist GLP-1/GIP range, but MASH is the primary target. If Phase 3 MASH data holds, pemvidutide enters a less crowded indication with a mechanistic advantage — direct hepatic fat oxidation — that pure weight-loss drugs don't provide.
Mazdutide
At a glance
| Field | Details |
|---|---|
| Brand names | Not yet globally branded |
| Targets | GLP-1R + GCGR |
| Developer | Innovent Biologics / Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Approved — China 2025. Not yet approved US/EU |
| Key efficacy | ~14.5% weight loss at 24 weeks (Phase 3 GLORY, China) |
| Indications | Obesity |
User Sentiment
Mazdutide's patient community is in China, where it's approved. Western discussion is mostly among researchers and pipeline watchers. Chinese patient forums report outcomes consistent with the GLP-1/glucagon class — strong appetite suppression with the distinct energy expenditure increase the glucagon component produces.
Example(What the community says)
Chinese health platforms show active discussion among mazdutide patients noting that the drug "feels different" from GLP-1-only options — particularly around energy levels and the speed of early weight loss. The glucagon agonism raising metabolic rate appears experientially distinct from appetite suppression alone.
How it works
GLP-1/glucagon dual agonist — same receptor framework as survodutide and pemvidutide. GLP-1R handles appetite suppression and insulin. GCGR adds energy expenditure and hepatic fat targeting. Developed by Innovent with Eli Lilly's commercial involvement, and the first drug of this mechanistic type to receive regulatory approval anywhere in the world.
Definition(First in class — globally)
Regulatory firsts matter because they demonstrate that a mechanism is acceptable to regulators, establish the safety database expectations for the class, and force competitors to respond. Mazdutide's China 2025 approval is the first anywhere for GLP-1/glucagon dual agonism — before survodutide, before pemvidutide, before anything in the West. That means the Chinese NMPA has reviewed and accepted this mechanism for approval, establishing a precedent that Western regulators will note.
Trial data
GLORY trials (Phase 3, China, 24 weeks): ~14.5% weight loss. Shorter trial duration than Western comparators — the 24-week number likely understates the full efficacy at 48–72 weeks, consistent with how other GLP-1 class drugs show continuing weight loss beyond 24 weeks.
What to Expect
Based on Chinese Phase 3 GLORY data and GLP-1/glucagon mechanism:
Month 1–2 — GI side effects during titration, appetite reduction early.
Month 3–6 — 10–12% weight loss range at 24 weeks (GLORY data). Weight loss expected to continue past 24 weeks based on class behavior.
Energy and metabolism — The glucagon component's effect on resting metabolic rate is reported as a distinct "lighter" feeling by some patients, separate from reduced appetite.
Not available in the US or EU — global filing timeline not yet public.
Dosing and administration
Once-weekly subcutaneous injection per China-approved protocol. Global dosing pending Phase 3 [verify global trial design].
Development status
| Milestone | Status |
|---|---|
| China approval | 2025 |
| Global Phase 3 | [verify status] |
| FDA filing | Timeline not public |
Safety profile
Phase 3 data from China consistent with GLP-1/glucagon class profile. Full global safety database pending.
Who It's For
- Currently only available in China
- BMI ≥ 28 (Chinese obesity criteria differ from Western BMI thresholds)
- People with obesity and type 2 diabetes — both indications in the Chinese approval
Western patients: mazdutide's approval establishes the regulatory precedent for GLP-1/glucagon dual agonism. Survodutide and pemvidutide are the Western development path for this mechanism.
Summary(The mazdutide picture)
The first approved GLP-1/glucagon dual agonist, anywhere in the world. 14.5% at 24 weeks likely understates full efficacy — most GLP-1 drugs continue losing weight through 48–72 weeks. The Lilly partnership provides commercial infrastructure; the global filing timeline is the key question.